Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Takeda's MRs to Deal with All of Its Products: Mr Yamanaka
July 16, 2007
- Nippon Shinyaku to Rebuild Pipeline with Niche Products: New President Maekawa
July 16, 2007
- Adhesives Most Preferred Dosage Form of Narcotics for Cancer Pain
July 16, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 16, 2007
- Research to Prevent Progression of CKD to Dialysis to Start
July 16, 2007
- Expenditures under NHI Programs in 2006 Rose Only 0.5%
July 16, 2007
- R&D NEWS IN BRIEF
July 16, 2007
- Draft Guidance for MD Studies Presented
July 16, 2007
- 420 Generics Receive NHI Price Listing
July 16, 2007
- Astellas, Kyoto Univ. Start Collaborative Drug Discovery
July 16, 2007
- Differences in Opinion over Generics Sharpen between JMA and Bill Payers
July 9, 2007
- 27% Sales Growth for Philips Medical Systems in Japan in 2006: Dr Smit
July 9, 2007
- seminar／Generic Substitution Essential to Further Promote Use of Generics: Dr Masuhara
July 9, 2007
- Eisai Aims at 20% Increase in Sales of Actonel with Once-Weekly Formulation
July 9, 2007
- GENERICS NEWS IN BRIEF
July 9, 2007
- Yakult Licenses Anticancer Agent Satraplatin from GPC Biotech
July 9, 2007
- Cephalon to File NDA for Bendamustine in US: SymBio
July 9, 2007
- GSK Deploys 630 Specialist MRs to Promote Adoair
July 9, 2007
- Nat'l Centers Should Form Healthcare Clusters to Promote Clinical Research
July 9, 2007
- GSK to Launch 5 New Drugs for Cancer in Next 3 Years
July 9, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…